von Redaktion LCGC | Dez 15, 2011
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK Journal: Clinical Cancer Research. Vol 17, No 23,...
von Redaktion LCGC | Dez 15, 2011
Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model Vansteenkiste J, Solomon B, Boyer M, Wolf J, Miller N, Di Scala...
von Redaktion LCGC | Dez 15, 2011
Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma A, Boellaard R, Neumaier B, Ullrich R, Holstein A,...
von Redaktion LCGC | Okt 15, 2011
A crucial requirement for Hedgehog signaling in small cell lung cancer Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, Bernard K, Conklin JF, Szczepny A, Yuan J, Guo R, Ospina B, Falzon J, Bennett S, Brown TJ, Markovic A, Devereux WL, Ocasio CA,...
von Redaktion LCGC | Sep 15, 2011
Personalized therapy of lung cancer cokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, and Jaehde U Journal: Clinical Pharmacokinetics, Vol 50, No 9,...
